Longitudinal Real-world Clinical Outcomes Study on Symplicity Renal Denervation (SPYRAL CARE)
Real-world Clinical Outcomes in Medicare Patients With Hypertension Treated With Symplicity Renal Denervation Plus Standard of Care Versus Standard of Care in Integrated EHR and Claims Data
Sponsor: Medtronic Vascular
Listed as NCT07174622, this observational or N/A phase trial focuses on Cardiovascular Diseases and Hypertension and remains actively recruiting participants. Sponsored by Medtronic Vascular, it has been updated 4 times since 2025, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Study Description(click to expand)The SPYRAL CARE study is an observational, non-interventional study of the Medicare population with uncontrolled hypertension treated with either the Symplicity RDN system plus standard of care (SOC) or with SOC alone. SOC reflects active management of hypertension. The study will evaluate real-world clinical outcomes by examining deidentified, longitudinal data from administrative health insurance claims linked with EHR. The primary objective is to assess the change in office systolic blood pressure at two years for patients treated with Symplicity RDN plus SOC compared to similar patients receiving SOC alone. The secondary objective is to describe major adverse cardiac events over a two-year period in both groups. The study analysis is subject to a central Institutional Review Board (IRB) review. However, individual hospitals are not engaged in research, and local IRB oversight is not necessary.
The SPYRAL CARE study is an observational, non-interventional study of the Medicare population with uncontrolled hypertension treated with either the Symplicity RDN system plus standard of care (SOC) or with SOC alone. SOC reflects active management of hypertension. The study will evaluate real-world clinical outcomes by examining deidentified, longitudinal data from administrative health insurance claims linked with EHR. The primary objective is to assess the change in office systolic blood pressure at two years for patients treated with Symplicity RDN plus SOC compared to similar patients receiving SOC alone. The secondary objective is to describe major adverse cardiac events over a two-year period in both groups. The study analysis is subject to a central Institutional Review Board (IRB) review. However, individual hospitals are not engaged in research, and local IRB oversight is not necessary.
Status Flow
Change History
4 versions recorded-
Apr 23, 2026 — Present [daily]
Recruiting
-
Feb 2026 — Apr 2026 [monthly]
Recruiting
-
Nov 2025 — Feb 2026 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Oct 2025 — Nov 2025 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
This observational study will assess the long-term effectiveness of the RDN procedure for lowering blood pressure in Medicare patients with uncontrolled hypertension. This research will be conducted using de-identified electronic health records (EHR) and administrative health insurance claims data. Patients are enrolled through the submission of claims or encounter data to CMS.
Contact Information
- Medtronic Vascular
For direct contact, visit the study record on ClinicalTrials.gov .